DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma.

BACKGROUND: Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS mutation status, and combination with docetaxel has demonstrated synergy in xenograft models. The aim of this study was to assess t...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Gupta, A, Love, S, Schuh, A, Shanyinde, M, Larkin, J, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Collins, L, Wise, A, Asher, R, Lisle, R, Middleton, MR
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	Oxford University Press 2014

Ижил төстэй зүйлс

DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
-н: Gupta, A, зэрэг
Хэвлэсэн: (2013)

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma
-н: Gupta, A, зэрэг
Хэвлэсэн: (2020)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
-н: Robert, C, зэрэг
Хэвлэсэн: (2013)

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
-н: Robert, C, зэрэг
Хэвлэсэн: (2013)

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
-н: Kirkwood, J, зэрэг
Хэвлэсэн: (2012)

Improved survival with MEK inhibition in BRAF-mutated melanoma.
-н: Flaherty, K, зэрэг
Хэвлэсэн: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
-н: K. Haslett, зэрэг
Хэвлэсэн: (2021-05-01)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
-н: Edmund Poon, зэрэг
Хэвлэсэн: (2017-08-01)

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
-н: Jessie Villanueva, зэрэг
Хэвлэсэн: (2013-09-01)

Immunological effects of BRAF+MEK inhibition
-н: Paolo A. Ascierto, зэрэг
Хэвлэсэн: (2018-09-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
-н: Eva Marie Erfurth, зэрэг
Хэвлэсэн: (2024-12-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
-н: Andrea Gazzin, зэрэг
Хэвлэсэн: (2024-06-01)

Identification of the Major Degradation Pathways of Selumetinib
-н: Tahar Sif eddine Bouchema, зэрэг
Хэвлэсэн: (2022-11-01)

A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib in combination with the oral MEK1/2 inhibitor selumetinib in solid tumors
-н: Pacey, S, зэрэг
Хэвлэсэн: (2016)

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
-н: Anne L Estep, зэрэг
Хэвлэсэн: (2007-12-01)

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma
-н: Sara Bjursten, зэрэг
Хэвлэсэн: (2019-11-01)

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
-н: Sarah J. Welsh, зэрэг
Хэвлэсэн: (2015-03-01)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
-н: Blessie Elizabeth Nelson, зэрэг
Хэвлэсэн: (2023-05-01)

Effect of food on capsule and granule formulations of selumetinib
-н: Sarit Cohen‐Rabbie, зэрэг
Хэвлэсэн: (2022-04-01)

Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity
-н: Hui-Ju Huang, зэрэг
Хэвлэсэн: (2021-06-01)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
-н: Leijen, S, зэрэг
Хэвлэсэн: (2011)

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
-н: Leijen, S, зэрэг
Хэвлэсэн: (2011)

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma
-н: Bengt Tholander, зэрэг
Хэвлэсэн: (2020-10-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
-н: Ken Saijo, зэрэг
Хэвлэсэн: (2022-08-01)

Autoimmunity associated with Erdheim-Chester disease improves with BRAF/MEK inhibitors
-н: Anaïs Roeser, зэрэг
Хэвлэсэн: (2019-11-01)

Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
-н: Lovisa Falkman, зэрэг
Хэвлэсэн: (2024-04-01)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
-н: Clare Judith Stones, зэрэг
Хэвлэсэн: (2013-05-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
-н: Jan Leipe, зэрэг
Хэвлэсэн: (2019-06-01)

Case report: Metastatic BRAF V600E–mutated adult Wilms’ tumor with robust response to BRAF/MEK inhibitor therapy
-н: Matthew R. Kroll, зэрэг
Хэвлэсэн: (2024-07-01)

Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy
-н: Shivshankari Rajkumar, зэрэг
Хэвлэсэн: (2022-04-01)

Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
-н: J. Steininger, зэрэг
Хэвлэсэн: (2024-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
-н: I. V. Samoylenko, зэрэг
Хэвлэсэн: (2017-11-01)

Exceptional response to rechallenge of BRAF/MEK inhibitors in patients with primary acquired resistance to targeted therapy
-н: B. Ziółkowska, зэрэг
Хэвлэсэн: (2024-01-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
-н: Michael J. Vido, зэрэг
Хэвлэсэн: (2018-11-01)

Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
-н: Zeynep Eroglu, зэрэг
Хэвлэсэн: (2016-01-01)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
-н: Raphael Reinhard, MD, зэрэг
Хэвлэсэн: (2018-03-01)

A case of malignant transformation of a serous borderline ovarian tumor effectively treated with BRAF/MEK inhibitor combination
-н: Manrose Singh, зэрэг
Хэвлэсэн: (2024-08-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
-н: Sivakamavalli Jeyachandran
Хэвлэсэн: (2024-06-01)

High BRAF V600 Mutation Level Associated with Worse Outcome in Metastatic Melanoma Patients Receiving BRAF and MEK Inhibitors
-н: Ariane Fizazi, зэрэг
Хэвлэсэн: (2024-11-01)

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study
-н: Marit A. C. Vermunt, зэрэг
Хэвлэсэн: (2021-08-01)